Skip to main content
. 2017 Sep 23;8(54):92265–92274. doi: 10.18632/oncotarget.21182

Figure 1. A subset of ALK-positive non-small cell lung cancer (NSCLC) patients have high serum ALK autoantibodies.

Figure 1

The ALK cytoplasmic domain (amino acids 1064-1620) was used to coat ELISA plates. ELISA O.D. values are shown using serum from ten patients with ALK-positive anaplastic large cell lymphoma (ALCL) from a previously reported series [14], 53 with ALK-positive NSCLC, and 38 with ALK-negative NSCLC. For each group, the median and standard deviation are shown. Samples used for subsequent Western blot analysis (for Figure 2) are delineated with arrowheads.